Experimental device requires no user input at all.
AZ also unveils promising results from early-stage lung cancer combination
How many pieces are left of the puzzle?
Brexit is already forcing parts of the medical device sector to leave the UK – will pharma have to follow?
Jon Williams, President of Evidera, is well-placed to offer his views on the issues impacting access to therapies.
Taking stock of one PRIME, of the EMA’s flagship market access initiatives.
11/06/2017August 29, 2017
19/09/2017August 21, 2017
06/09/2017August 2, 2017
‘Pricing and Market Access Outlook: 2017 Edition’ includes fresh analysis from QuintilesIMS of market forces and pricing policy based on facts and figures behind approvals of new molecular entities in 2015.